The scope of preclinical drug development: An introduction and framework

Preclinical Drug Development

Volumn , Issue , 2005, Pages 1-9

  Rogge, Mark C ^a  

^a ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85128142250     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (20)

1. Shapiro KJ. Looking at animal models: both sides of the debate. Lab Animal 1998; 27(10):26-29.
2. Parkinson C, Grasso P. The use of the dog in toxicity tests on pharmaceutical compounds. Hum Exp Toxicol 1993; 12:99-109.
3. Vos JG. Immunotoxicity assessment screening and function studies. Arch Toxicol 1980; 4:95-108.
4. Penta JS, Rosencweig M, Guarino AM. Mouse and large animal toxicology studies of 12 antitumor agents: relevance to starting doses for phase i clinical trials. Cancer Chemotherapy Pharmacol 1979; 3:97-101.
5. Chien JY, Mohutsky MA, Wrighton SA. Physiological approaches to the prediction of drug-drug interactions in study populations. Curr Drug Metab 2003; 4(5):347-356.
6. Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001; 120:411-420.
7. Pharmaceutical R&D Spending: Pharmaceutical Research and Manufacturers of America. PhRMA Annual Survey, 2001.
8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 1998; 279(15):1200-1205.
9. Martignoni M, Monshouwer M, de Kanter R, Pezzetta D, Moscone A, Grossi P. Phase I and Phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation. Toxicol In Vitro 2003; 18(1):121-128.
10. Salonen JS, Nyman L, Boobis AR, Edwards RJ, Watts P, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, Ingelman-Sundberg M, Hidestrand M, Guillouzo A, Corcos L, Goldfarb PS, Lewis DF, Taavitsainen P, Pelkonen O. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos 2003; 31(9):1093-1102.
11. Bonate PL, Reith K, Weir S. Drug interaction at the renal level, implications for drug development. Clin Pharmacokinet 1998; 34(5):275-404.
12. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42(10):883-908.
13. Martin-Jimenez T, Riviere JE. Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline. J Pharmaceut Sci 2002; 91(2):331-341.
14. Mahmood I, Balian JD. The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokinet 1999; 36(1):1-11.
15. Lin JH. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 1998; 26(12):1202-1212.
16. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmaceut Res 1993; 10(7):1093-1095.
17. Tugwood JD, Hollins LE, Cockerill MJ. Genomics and the search for novel biomarkers in toxicology. Biomarkers 2003; 8(2):79-92.
18. Marcusson-Stahl M, Cederbrant K. A flow-cytometric NK-cytotoxicity assay adapted for use in rat repeated dose toxicity studies. Toxicology 2003; 193(3):269-279.
19. Nagami K, Kawashima Y, Kuno H, Kemi M, Matsumoto H. In vitro cytotoxicity assay to screen compounds for apoptosis-inducing potential on lymphocytes and neutrophils. J Toxicol Sci 2002; 27(3):191-203.
20. Yang A, Cardona DL, Barile FA. In vitro cytotoxicity testing with fluorescence-based assays in cultured human lung and dermal cells. Cell Biol Toxicol 2002; 18(2):97-108.